SUMMARY Fifty two sick neonates with major duct dependent cardiac defects were given short term intravenous infusions of prostaglandin E1 (alprostadil) in doses varying between 0-005 and 0.1 ,ug/kg/minute. The object of the study was to try to achieve an effective but safe regimen that could be instituted as soon as such a diagnosis was suspected. Effective clinical improvement was achieved at each dosage but the incidence of side effects seemed to be dose related, and no serious side effects were noted at a dosage of 0-005 to 0-01 [tg/kg/minute. It is recommended that a low dosage regimen be started before transfer to a paediatric cardiac centre.
The role of prostaglandins in maintaining ductus patency in the newborn infant is now well established and there are numerous reports of the successful use of prostaglandin El and prostaglandin E2 in sick newborn infants with both cyanotic" and acyanotic-6 ductus dependent cardiac malforma- tions. These reports have mainly been concerned with the administration of prostaglandins once an exact cardiac diagnosis has been established. The object of this study was to establish a safe and effective regimen for prostaglandin El that could be initiated on suspicion of a duct dependent cardiac defect in a sick neonate, either shortly after arrival at a paediatric cardiac centre or, perhaps more importantly, before transfer to such a centre. There would thus be the optimum chance of maintaining or improving such an infant's general status before urgent cardiac investigations and surgery, contributing to an improvement in morbidity and mortality in this group of critically ill neonates.
Our experience with prostaglandin El dates from 1978 when we started to use it in individual clinical treatment for sick infants with proved major duct dependent cardiac malformations. The current series covers a three year period from 1980 and utilises a standard regimen of administration based on our earlier experience, the only variable factor being that of dosage.
Patients
The patients consisted of 52 consecutively admitted sick infants suspected of having major ductus dependent cardiac defects. Preterm infants, those requiring assisted ventilation, and any in whom clinical and arterial blood gas data were inadequate were excluded. Prostaglandin E1 was started after clinical diagnosis of a major cardiac defect whose clinical course would be adversely affected by ductus closure. The cardiac diagnosis was subsequently confirmed by two dimensional echocardiography and by angiography (48 patients) or two dimensional echocardiography alone (four patients). The patients were divided into three groups. Group 1 consisted of 24 cyanotic infants with ductus dependent pulmonary blood flow (simple or complex pulmonary atresia (22 patients) and critical pulmonary stenosis (two patients)). Group 2 consisted of 18 patients with ductus dependent systemic blood flow (severe coarctation of the aorta (six), interrupted aortic arch (three), and hypoplastic left heart syndrome (nine)). Group 3 consisted of 10 infants with ductus dependent systemic-venous mixing (simple transposition of the great arteries). The initial inclusion of infants in the third group was because of unavoidable delay in access to the catheter laboratory and hence of balloon atrial septostomy.
The infants were assessed clinically, and upper and lower limb blood pressures were recorded. A chest radiograph and electrocardiogram were carried out on each infant. Observations of rectal temperature, apex, and respiratory rate were made; radial artery blood gases were estimated within an hour of starting prostaglandin E1 and were repeated one to four hours after the start of treatment. Any side effects attributable to prostaglandin E1 were recorded, and pyrexia was defined as a temperature of above 3720C occurring more than once in 24 hours.
The ages of the infants on beginning prostaglandin treatment ranged between 6 hours and 16 days. The older infants were in group 2. Twenty of the infants were less than 24 hours of age. The group 1 infants were all less than 8 days old and the group 3 infants less than 4 days old. The decision to give prostaglandin E1 was based on the clinical diagnosis of a duct dependent cardiac defect. The group 1 and 3 infants had increasing cyanosis, with or without metabolic acidosis. The arterial Po2 varied from 2*0 to 4-6 kPa (15-0 to 34-6 mmHg) in group 1 infants (Fig. 1) 
Side effects
The side effects ascribed directly to prostaglandin El are described in Table 2 . Forty one episodes were recorded in 19 infants, 12 of whom had more than one side effect. The most serious side effect was of sudden apnoea which occurred in four cyanotic infants in group 1 within four hours of starting prostaglandin El. Hypoventilation and abnormal breathing patterns were noted in six additional infants in whom respiration had been rapid but regular before starting the treatment. Nine infants became 'jittery' within four hours of starting treatment and two developed generalised convulsions. Frequent loose stools were documented in at least catheter could not be passed to the left atrium so it was supposed that the infant had premature closure of the foramen ovale and emergency surgical septectomy was carried out. Despite the possibility of this problem, our policy is to utilise prostaglandin El for sick infants suspected of having transposition of the great arteries, particularly if there is a predicted delay in access to laboratory facilities for balloon atrial septostomy. It is also our current practice to arrange for prostaglandin El treatment to be started before transfer in any infant judged to have a major duct dependent cardiac defect after telephone discussion with the referring paediatrician.
Despite awareness of the possibility of side effects, it may be difficult to decide whether a particular complication results directly from prostaglandin treatment or whether it could have been coincidental in the clinical course of a sick neonate, 16 and reports on the incidence of known side effects are few. In a large multicentre study of 481 infants, however, 21-5% had one or more documented side effect,'6 compared with 36-5% in our own series.
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